Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a new MRI scan reveal the Brain's hidden repair process in MS?

NCT ID NCT03600779

Knowledge-focused Sponsor: Assistance Publique Hopitaux De Marseille Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 06, 2026 · Last updated Aug 07, 2026 · Updated 1 time

Summary

This study tests whether a new MRI technique, called inhomogeneous Magnetisation Transfer (ihMT), can accurately measure myelin damage and repair in people with multiple sclerosis (MS). The researchers will compare ihMT scans with standard MRI measures in 85 adults with early-stage MS and healthy controls. The goal is to see if ihMT can serve as a reliable biomarker for monitoring the disease and the effects of future remyelinating therapies.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
inhomogeneous Magnetisation Transfer (ihMT) MRI sequence
What this could lead to
If successful, this could provide a way to see myelin damage and repair in real time, helping to monitor MS and evaluate future remyelinating therapies.
What could go wrong
This is an early imaging study, not a treatment trial. The technique may not prove sensitive enough or may not translate into routine clinical use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 85 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2018

Expected to finish

Aug 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 45 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * For Patients and Controls : * Adult patient, male and female, age 18 to 45 * Patient affiliated with health insurance coverage, * Patient who signed a free and informed consent after receiving detailed, understandable and honest information, * For patients only : * Patient with relapsing-remitting multiple sclerosis according to the McDonald 2010 criteria or progressive * Patients treated or not treated with first-line disease modifying therapy * Detection of at least one post-Gadolinium injection active lesion identified on the initial brain MRI (T0) or a chronic active lesion (PRL: Paramagnetic rim lesions) Exclusion Criteria: * For patients only : • Patients with a progressive form of MS other than the early relapsing-remitting form (primary progressive or secondary progressive) * For Patients and Controls : * Patients with the usual contraindications for MRI (pacemaker, agitation, metal shards, claustrophobia) * Patients at risk of non-compliance to the exam: basic problems with understanding, confusion, involuntary movements, poor tolerance of prolonged supine position * Patients who are unable to give their consent: problems with understanding, lack of vigilance, confusion * Woman who is pregnant and breastfeeding * Patients with a history of neurological or psychiatric condition * Patients under guardianship or trusteeship

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Relapsing-remitting multiple sclerosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

multiple sclerosis relapsing-remitting multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Sclerosis, multiple

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Assistance Publique Des Hotipaux de Marseille

    RECRUITING

    Marseille, PACA, 13354, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.